Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 2mg | $34.99 | $17.50/mg | Out of stock | Jun 1 |
| vial | 5mg | $54.99 | $11.00/mg | Out of stock | Jul 7 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| 394895 | Feb 2025 | 98.7% | SafeCert Labs | — | Unverified | View |
| CC10-001 | Nov 2024 | 99.4% | Janoshik Analytical | — |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. CJC-1295 is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Peptide Tech sell CJC-1295?
Yes — Peptide Tech currently lists CJC-1295 in 2 variants starting at $54.99 ($11.00/mg).
Is Peptide Tech's CJC-1295 third-party tested?
Yes — Disclosed Labs has indexed 3 Certificates of Analysis for Peptide Tech's CJC-1295, with the most recent showing 98.7% purity. Peptide Tech holds an overall trust grade of C (78/100) across all 219 COAs on file.
What is Peptide Tech's trust grade for CJC-1295?
Peptide Tech has an overall Disclosed Labs trust grade of C (78/100), computed from 219 COAs across all peptides. The most recent CJC-1295 COA was issued by SafeCert Labs.
Where is the cheapest CJC-1295?
As of the latest data, Peptide Supply Co. offers CJC-1295 at $3.80/mg — compare with Peptide Tech's listing at $11.00/mg. See the full CJC-1295 price comparison.
Is CJC-1295 legal to buy?
CJC-1295 is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
| View |
| CC-001 | Jul 2024 | 99.1% | Janoshik Analytical | — | Unverified | View |
Disclosed Labs